Moderna reports fourth quarter and fiscal year 2022 financial results and provides business updates

Fourth quarter 2022 revenues of $5.1 billion; gaap net income of $1.5 billion and gaap diluted eps of $3.61 full-year 2022 revenues of $19.3 billion; gaap net income of $8.4 billion and gaap diluted eps of $20.12 company reiterating approximately $5 billion in covid-19 sales contracted for delivery in 2023 and expecting additional sales from key markets company will file for regulatory approval for mrna-1345, moderna's investigational rsv vaccine for older adults, in the first half of 2023. mrna-1345 was recently granted fda breakthrough therapy designation mrna-1010 phase 3 flu vaccine interim efficacy analysis expected to be reviewed by an independent dsmb before the end of the first quarter mrna-4157, moderna's investigational personalized cancer vaccine in combination with keytruda®, was granted breakthrough therapy designation; full data set to be shared at upcoming medical oncology meeting and in peer reviewed publication company r&d investments planned to increase to $4.5 billion in 2023 cambridge, ma / accesswire / february 23, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today reported financial results and provided business updates for the fourth quarter and fiscal year 2022.
MRNA Ratings Summary
MRNA Quant Ranking